Dhillon Punit
- SEC CIK
- 0001425052
No open-market purchases or sales filed in the past year.
Current role at each company
- SKYE Skye Bioscience, Inc.Chief Executive Officeras of Aug 7, 2026
- ARTH Arch Therapeutics, Inc.Directoras of Nov 10, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Dhillon Punit as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
SKYE Skye Bioscience, Inc.
Chief Executive Officer2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 19, 2024 (view filing) | Nov 15-18 | 4 days | Dhillon PunitChief Executive Officer | SSale | −82.9K | $4.99 | −$413.9K | −20.1%329.8K after | 2 lots |
| Aug 31, 2023 (view filing)11:26 AM ET | Aug 29 | 2 days | Dhillon PunitChief Executive Officer | PPurchase | +881.0K | $0.0187 | +$16.5K | +3.6%25.7M after | Amended |